21．エイズ研究センター
Contents
1. LC FRE ERR EZULCISVVUC G4 V8 WMA 4 V3 IgG V3 36 V3 in vitro SHIV 6 SIV gag BCG DIls2. 2 SHIV SHIV 89 6P clone64 Clone64 SHIV C2 1 KS661 C2 1 CD4 3 Clone64 C2 1 5 3 5 Clone64 3 C2 1 4 3
3. 8 7 10 15 64 2003 12 5561 1156 ALL RSA FESP MREP WEST GEV UT VTE 2 HIV 1
4. 15 12000 diketo acid strand transfer HE TEE Ze SUF Rn RA Sete T sHE I PERE KR 9 15
5. HIV MEME UOM HIV JROOERBOERAR FORA HIV HIV HS 5 1 HS
6. 30 Human Trial 1 1 HIN CREOLAE Gass prime boost SIV SHIV KS 661c SIV Gag HIV 1 C
7. RT RT 400bp HIV 1 5 HIV 1 HIV 1
8. M8166 HIV 1 HIV 1 gag pol BR E 4 HIV 1 MaRBLE cell HIV 1 14 T HPB M a LTR EGFP RFP firefly 1 usiferase CMV renila luciferase HIV 1 MaRBLE cell RFP firefly luciferase p24
9. 7 PSED Dis HIV Gag pol rDIs HIV Gag pol PSEJ rDIs HIV Gag pol HE PSF HIV SIV Gag pol rDIs HIV Gag pol 8 DNA Dis DNA Ds CD
10. UICA NIH Z JICA HIV 1 FA HS 2 PE ET TE DE 2 15 4 1 RD 4 1 5 1 2 5 1 2 16 1 1
11. HE H15 10 27 12 5 JICA 1 HIV t Jif H15 9 12 9 14 2 HIV 1 H15 10 27 12 5 JICA 1 HIV o A H15 7 7 JICA H15 7 23 JICA H15 10 9 21 JICA H15 10 27 12 5 JICA 1 HIV H15 11 7 11 9 JICA AIDS ATL
12. JE CMV 140 4 oM HS EBV CMV JCV PCR EBV CMV JCV DNA 22 1 11 4 0 1 CT B OPS VANS SFT CET ENGEL OR
13. 4 HIV HIV 1 HAART HIV 1 HIV 1 HIV 1 HIV 1 HIV 1 HIV 1 in vitro HIV 1
14. Bnv 4 HGRA Env CD4 PEE RA SIVmac239 A5G Env A5G A5G OR LA OS
15. HIV 1 TA 5 10 HIV 1 nascent HIV 1 HIV 1
16. 1998 subtype C plndie C1 subtype C 1 2002 Zambia HIV Trapping System Long PCR Amplicon Half amp Half Strategy 8 9 1 subtype C 2 MAGIC5A NP2 PBMC
17. DB WEB DB 16 3 DDBJ HIV F DB 100 017 F HIV 572 3217 C2VS3 361 V3 361 PDB CD4 DDBJ HIV genosubtyping division V3 3 DB 1 14 10 WEB V HV 1 HIV 1 HIV l EUN IO gp41 HIV 1 ORBITS LC ORBEA ICY CS Ik
18. HIV 1 CD4 ES T HeLa 5 PINFV SQV LPV RTV IDV 2 5uM HPB M a 20 PI HPLC PI HPB M a NFV 134 4 SQV 92 6 LPV 11 9 RTV 11 8 IDV 3 1uM NFV 10uM HeLa HPB M a 20 HeLa NFV 180uM HPB M a 880uM 1 5 PI AL MEESE BID KS 10 CRFO1_AE NH3
19. HIV HIV HS HIV JST HIV HIV 1
20. w BEHS AI E 12 DRIT ORRERI AMRES 4 7v 2003 1 24 2244 5 HIV 1 2 HBs TP HCV HTLV 1 HIV 1 HBsAg 10 2 TP 20 4 HCV 9 8 HIV 11 8 HTLV 1 0 06 56 6 Pailin 33 3 20 Phnom Penh 33 4 Sihanoukvile Port Kompong Som 32 4 Krong Kep 25 0 Koh Kong 22 7 HIV 1 HIV 239 BID gag env CREFO1
21. HAART RT PBMC L210W T215Y M41L Ins69 T69 RT PBMC 2 0B I UC UTIL RT Sacl in vitro
22. B B non B E nelfnavir E D30N N88S 15 CRFOLAE D30N WSS PAB TREAT Vif Univ Massachusetts 7 HIV 1 HIV
23. HIV 4 HIV 17 2003 11 27 29 TA Gag p17 HIV 1 CRF01 AE 17 2003 11 27 29 17 2003 11 27 29 KD 247 17 2003 11 27 29 amp ME ft HIV 1 KD 247 17 2003 11 27 29 TIRE me BHA fu RD ft HIV 1
24. HIV 1 SERCH Bae SK OBER UNI BO HIV 1 T HIV 1 3 Arp2 3 Arp2 3 endocytosis Arp2 3
25. HIV HIV Aue 1 HIV TU HIV HAART 2 HIV 1
26. III HIV 1 HIV 1 CRF08 BC 2000 CRF08 BC HH040 5 LTR pbs 800 bp pbs D 3 LTR 9000 bp D PBMC 2 g 44 Pa AK NXOS dec WU SUD om S PBMC NX22 kinetics CXCR4 CCR5 HH040 2 NP PBMC NX4 gp160 gp120 CRFO08_BC C B
27. E JH By Ef JST IHIV GE HIV 1 HIV HS HS BEJA
28. Vif NL4 3 B 3 BE Jey All HERY EREC Y WKKW UR 5 HIV HIV SIVgag SIVgagDNA HIVenvDNA lgG IgA M3 DPPE PolyIC
29. HIV 1 51 2003 10 27 29 Inhibition of HIV 1 replication using a single transcriptional unit that expresses decoy and SiRNAs in cells 51 2003 10 27 29 B HERO AIDS AIDS 2003 10 30 HIV E 52 2003 10 30 B WSERCE DIs 17 2003 11 27 29 RIE PARE
30. 17 2003 11 27 29 A HAART F HIV ME Z 17 2003 11 27 29 AH Ed M Lay Myint WWT AL CRFOLAE 39 40 41 42 43 44 45 46 47 Ne 48 49 17 2003 11 27 29 T R Lay Myint WWFT RD CRFOl AE 17 2003 11 27 29 H M HIV lprotease 17 2003 11 27 29
31. 3 All in One Assay JST Phenotype HIV 1Full Genome GenoPhenotyping BCL BCL E 3 HIV 1 v1 5 HIV 1 1 1 38 30 29 HIV
32. 2 2004 in press 2004 APS ATL MEH JY SARS 129 2004 Il 1 1 Nakasone T Yamamoto N Izumi Y Matsuo K Ami Y 2 3 4 Yamazaki S Honda M Prime boost vaccination with recombinant Mycobacterium bovis bacillus Calmette Gu rin and vaccinia strain Dls elicits protective immunity against pathogenic SHIV infection 10th Conference on Retroviruses and Feb 10 14 2003 Boston in macaques Oppotunistic Infections USA Nakasone T Izumi Y Matsuo K Ami Y Someya K Kanekiyo M Hamano T Horibata S Yoshino N Hara T Takizawa M Kawahara M Kaizu M Hamatake M Sakai K Shinohara K Yamazaki S Yamamoto N Honda M with recombinant Prime boost vaccination Mycobacterium bovis bacilus Calmette Gu rin and vaccinia strain DIs elicits protective immunity against pathogenic SHIV infection in macaques Japan U S Cooperative Medical Science Program 14th Joint Meeting of AIDS Panel Mar 5 7 2003 Okinawa Kozyrev IL Miura T Sak
33. 5 gag CD4 T J MHC II allele MHC haplotype 2 SIV SHIV RT gag CD4 T gag peptide epitope Mm9703 gag262 271 YRRWIQLGLQ 10 Mm9429 gag261 272 IYRRWIQLGLQK 12 MHC haplotype 2 FEM DR alleles DRB w2002 DRB w2501 293T gag peptide CD4 T DRB w2501 Mm9703 CD4 T gag Mm9429 allele DRB w2002 CD4 T Mm9703 CD4 T DRB w2501 gag262 271
34. 4 2 Bnv gp41 2 Clone64 C2 1 Bny gp41 Iouri L Kozyrev J 3 SIVmac239 SIVmac239 gp120 22 N 5 A5G A5G SIVmac239 8 CARP bs
35. HIV 1 copy pBR322 MCS HIV 1 pMT 5 pMT1 HIV 1 Se 2 Half and Half Full genome DNA 5 LTR PBS pBR322 Cloning Vector pMT1 PBS Kas I 3 LTR PolyA signal Not I Primer 9 0 Kbp Long Amplicon HIV Database Vpr vif Rare cutter
36. HIV 1 HIV 1 JR CSF hu PBL SCID HIV 1RNA PBMC HIV 1 HIV 1 HIV 1RNA HIV 1 WREEF ARAT ABE CWS TREET VII 1 HIV 1988 HIV TEV ER 15 155 hemophilia 125 30 21 2004 6 4049 hemophilia 2875 1174 852
37. HIV HIV WM A HS HIV HIV IHIV 2c HIV HIV 1
38. DNA RNA 2 HIV gag p17 sequence CTL HIV Gag p17 circulating HIV 74 sequence 1 2 3 4 05 type virus circulating seroconvert L 72V type
39. 500 5 HIV 1 2 HBs TP HCV HTLV 1 HIV 1 2 0 2 HBsAg 3 8 HTLV 1 0 0 HCV 6 0 TPs 12 6 1999 HIV HIV 16 B HIV G TTV
40. 17 2003 11 27 29 Kozyrev IL su Genetic analysis of acute pathogenic and less pathogenic SHIV molecular clones to determine the responsive site for in vivo pathogenicity 17 2003 11 27 29 Z XR SIV attenuated virus 17 2003 11 27 29 Env 17 2003 11 27 29 50 51 52 Hagiwara Y Dohi T Yoshino N McGhee JR Fujihashi K Nontoxic CT EI12K Mutated In The COOH Terminal KDEL Of The A Subunit Elicits Mucosal Adjuvant Activity Without Intracellular Trafficking 33 2003 12 8 10 H
41. BCG SIV Gag BCG BCG DIs prime boost regimen BCG 4 Gag IFN y Dis BCG 4 Gag IFN y DIs BCG
42. Gag IgG 50 100 125 0 1 mg 2 6 Gag rBCG SIVGag 3 HIV 1 CRFOLAE 92TH022 HIV 1 CRFOLAE 92TH022 gag env BCG Dis BCG gag env DIls gag tie Env gp120 gag env BCG 4 HIV 1 V3 BCG Dis
43. 2 BCG 3 4 prime boost regimen R5 5 HIV Human Trial 1 HIV 1 subtypeC zs HIV 1 subtypeC HIV 1 subtypeC DB26 gag PCR BCG
44. 3 HIV HIV 1996 HIV 1 QOL NOD SCID commony SCID PBL hu PBL SCID HIV E ZOH HIV 1 DC PBMC CD14 DC DC CR ge XAb7e DC hu PBL SCID
45. 5 HIV 12 7 HIV 765 15 10 1 728 96 3 252 20 2 person year observation CD4 PD
46. HIV 1 Nef tk MHC 1 CD4 T HIV 1 Nef Nef Nef SeV MHC 1 PREP aoe REPT BA II HIV 1 HIV HIV 1 7 3 7 17 BHA Highly Active Anti Retroviral Therapy HAART AIDS
47. FEET HIV WEE SIERRA IHIV HIV HIV GE Ur Fo X I Phase IH Trial Vax Gen Recombinant Envelope
48. Xiaojie Li Yanling Ma Chaojung Yang Qianqiu Wang Xueshan Xia Kunlong Ben aa aN IV HIV 1 1 HIV 1 HIV 1 HIV 1 Zambia Ghana aa ET SE JERS 1 HIV 1 HIV 1 LTR FAIZ Toxic High copy MOTT A
49. HIV 1 OPER CARA SETS Ee TET HIV 1 in vitro HIV 1 HXB2 pol HRV3 pol gag p6 2 5 p24 HRV5 CRF01AE NH 1 HXB2 HRV3E HRV5E HRV3 HRV5 HRV3E HRV5E HRV3 18 4 HRV5 164 HXB2 1 NH1 HRV3E 23 9 HRV5E 24 3 NH1 1
50. 30 4 407 071 2003 HIV 1 31 4X 251 263 2003 2 RYLE pp 170 186 2003 EE Hoo SHED Be uw 13 14 15 16 17 18 4 14 20 2003 Vita HIV 2003 HIV 6 42 49 2004 HIV
51. E DNA rDis ERS SIV Thl SIV DNA V rDis Th1 LIRIE SHIV HIV 9 BCG a
52. 7 HIV 1 HIV CRFOLAE E B gag pol CRFO1_AE Gag 100 550bp B 2 fH 1 B er 8 HLA HIV
53. Mm9429 CD4 T R90 120 MHC haplotype B BLCL gag DRB w2501 293T R90 120 MHC haplotype B MHC II allele DRB w2501 BLCL 293T 2 CD4 T 2 1 hu PBL NOD scid R5 NOD seid PBL hu PBL NOD scid HIV 1 HIV 1 MNp X4 tropic R5 JRCSF
54. HIV 1 Gag cleavage site mutation CSM CSM non CSM HIV 1 HIV 1 gag Gag Lay Myint M ARAE 3
55. SIV MVASIV239gag pol rDIsSIVgag pol MVASIV239gag pol B n ft 5 f Y A LEX XIE SIV gag IFN y 2 SIV gag IFN y Dts MVA 2 2 HIV HIV CCR5 ELTON Cams 1 Rb
56. H15 6 22 6 27 A 2 OFA Sl H15 9 12 9 14 HIV 1 H15 10 2 10 8 A 2 H15 10 27 12 5 JICA 1 HIV H15 12 8 12 13 8 H16 2 2 2 14 11 H16 3 7 3 12 16 H16 3 27 3 31
57. HIV HIV re ELEM RBS 0000000000 HIV HIV 1 gm US uH E 5518075 4T E 55 48075 Ji E 25488 4T an S HIV HIV F HIV TI
58. Primer Vpr Vi pMT1 Vpr Vif Half amp Half Half amp Half Strategy NL4 3 MAGIC 5A Vpr EcoR I site Primer NL4 3 10 fae 3 Zambia HIV 1 subtype C UNAIDS 2003 HIV 4 200 subtype C HIV subtype B HIV subtype B subtype B minor subtype CHS subtype non B
59. 3 1 3 31 4 1 1 KA u JICA JICA NIH H15 7 23 JICA H15 12 10 14 8
60. 82 2000 Ag sLoTECU AS 2019 4 yee ABAD PCR HIV 1 1979 1994 HIV lgag nested PCR CHE HIV 1 VI 15 304 HIV 1 1984 4 43 1985 50 37 74 HIV 1 BX 12 76 2 6
61. 9 HIV HIV HIV HIV 1 T CTL HIV CTL CTL HIV CTL CTL CTL CTL HEAR A EALE 10
62. HIV 1 SIV Arp2 3 HA HSV 1 MLV Adenovirus Arp2 3 Arp2 3 VI HIV 1 1 Cell associated virus HIV Cell associated virus Cell free virus Cell associated virus Cell associated virus
63. subtype C Um Ak miis Gambia Francis Kasolo Zambia 4 Ghana HIV 1 Ghana HIV 1 subtype Ghana 25 7 28 D 29 Accura EDTA 2 Donor PBMC MAGIC5A Coculture Donor PBMC Coculture 12 25 MAGIC 5A Coculture 16 25
64. 51 2003 5 Ak E fe DANK 4 AX SRR A 4 1999 2002 HIV 21 2003 6 14 H XX F 7 8 9 10 11 12 13 14 15 16 EER C A HIV 21 2003 6 14 Cytoskeletal Support of Viral Life Cycle
65. HIV 1 RT PR NH HAART NH3 NRTI RT RT M41L D67N K70R L210W T215Y PBMC HIV 1 RT
66. seroconversion CTL 8 Pathom Sawanpanyalert NIH Thai Paijit Warachit NIH Thai Tawee Chotpitayasunondh Queen Sirikit National Institute of Child Health Warunee Punpanich Rajavithi Hospital 3 HIV IL 16 HIV 58 IL 16 level IL 16 HIV IZ in vitro IL 16 2 IL 16 PHS blast CBMC HIV 37 2 p24 IL 16 HIV IL 16 HIV
67. CMV renila luciferase renila luciferase renila luciferase THES SHAE TREE BASA AHH EL 5 AZT CRFOLAE E HIV 1 WHO 3 by 5 Initiative HIV 1 d 4T 3TC nevirapine HIV 1 HIV 1 HIV 1 HIV 1
68. Kawamoto H Nakasone T Honda M Hayami M Miura T The effects of pathogenic SHIV infection on the thymus and intrathymic T cell progenitor in rhesus monkeys 21th Annual Symposium on Nonhuman Primate Models for AIDS Oct 22 25 2003 Seattle USA Kozyrev IL Miura T Sakai K Takahashi E Shinohara K Suzuki H Ibuki K Hayami M Comparative analysis of acute pathogenic and less pathogenic SHIV molecular clones 21st Annual Symposium on Nonhuman Primate Models for AIDS Oct 22 25 2003 Seattle USA sugimoto C Shioda T Yasutomi Y Yamamoto N Nagai Y Mori K Properties of a quintuple deglycosylated SIVmac239 mutant as a novel attenuated SIV 21th Annual Symposium on Nonhuman Primate Models for AIDS Oct 2003 Seattle USA sugimoto C Ohgimoto S Kusakawa S Takebe Y shioda T Nagai Y Mori K Influence of deglycosylation 21th Annual Symposium on Nonhuman Primate Models for AIDS Oct 2003 Seattle USA on efficacy of Env based vaccine Yan H Chiba T Nomura N Kitamura Y Nishizawa M Matsuda M Yamamoto N Sugiura W Discovery of novel small molecule HIV 1 integrase inhibitory compounds 4th HIV DRP Symposium Antiviral Drug Resistance Dec 7 10 2003 Virginia USA Kantor R Shafer RW Efron B Carvalho AP WynhoveB n Soares MA Cane P Clarke J Snoeck J sirivichayakul S Ariyoshi K Holguin A Pillay C Rudich H Rodrigues R Bouzas MB Cahn P Brigido LF Grossman Z Morris
69. 21 Bo X 1981 2003 HIV 6 000 480 290 8596 2003 HIV 5 780 4 194 AK 1 586 2 892 2 487 405 HIV 1996 2003 640 573 67 28 56
70. 4 SIVmac239 gp120 A5G gp120 DNA SIVmac239 gp160 A5G gp160 Boost Boost f 8 SIVmac239 wt Env 2 A5G Env 2 SIVmac239 A5G SIVmac239 viral load wt Env A5G Env viral load set point wt Env A5G Env A5G 2 viral load wt Env A5G Env SIVmac239 1 10 1 100 viral load 6 A5G Env Env SIVmac239 A5G 7
71. HIV 1 17 2003 11 27 29 29 30 31 32 33 34 35 36 37 38 E REK TRE DAE HIV 2 17 2003 11 27 29 H E KEK PARE DAE HIV 3 HIV 17 2003 11 27 29 E RIEK
72. HIV RT 1 CDC Heneine RT Amp RT 2 HIV RT 3 HIV 1 RT RT 4 Amp RT TaqMan 0 8 copy 1 L ULZR2SOEE HIV AIDS
73. p27 IgG rDIsSIVGag 4 rDIsSIVGag rDIsSIVGag amp AARE SIVp27 p27 ELISPOT CD4 T Gag Th1 Th2 rDis 5 C4 V3 HIV
74. 3 rDIs SIVgag HIV DIsHIV HIV CD8 rDIs SIVgag SHIV
75. Kaizu M Ami Y Nakasone T Sasaki Y Izumi Y Sato H Takahashi E Sakai K Shinohara K Nakanishi K Honda M Higher levels of IL 18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV Virology 313 8 12 2003 Takizawa M Chiba J Haga S Asano T Yamamoto N Honda M Fractionation of guinea pig leukocyte by flow cytometry MILA SSC parameter Cytometry Research 13 25 32 2003 Izumi Y Ami Y Matsuo K Someya K Sata T Yamamoto N Honda M Intravenous inoculation of using a novel replication deficient recombinant vaccinia virus DIs expressing Simian Immunodeficiency virus gag controls highly pathogenic Simian human immunodeficiency virus J Virol 77 13248 13256 2003 Assawawitoontip 5 Puthavathana P Pattanapanyasat K Sukpanichnant S Thammataksin S Honda M Warachit P Lymphocyte and NK cell subpopulations in HIV in monkeys seronegative Thais Asian Pac J Allergy Immunol 21 95 103 2003 snoeck J Kantor R Shafer RW Derdelinckx I Carvalho AP Wynhoven B Soares MA Cane P Clarke J Pillay C Sirvichayakul S Ariyoshi K Holguin A Grossman Z Rodrigues R Bouzas MB Cahn P Brigido LF Soriano V Sugiura W Phanuphak P Morris L Weber J Pillay D Tanuri A Harrigan PR Camacho R JM Katzenstein D AM Evaluation of five interpretation algorithms for the Schapiro Vandamme prediction of drug susceptibility in non B subtype An
76. PH eet Arp2 3 26 2003 12 10 13 H PA eet HIV 1 53 54 membrane spanning domain MSD 26 2003 12 10 13 HIV AIDS 82 2004 1 31 Wek PE TEST A KA AMKOAETS HIV 1 124 2004 3
77. ELISPOT 6 Env Bnvy PL OREGAICFE DIVCOW HD SIVmac239 gp120 NN 5 A5G SIVmac239 SIVmac239 A5G Env Env Env SIVmac239 A5G 8
78. H15 11 30 12 12 JICA H15 10 27 12 5 JICA 1 HIV A 5 7k HI5 10 27 12 5 JICA 1 HIV A H15 7 25 JICA Molecular Biology of HIV 1 H15 10 27 12 5 JICA 1 HIV A H15 10 27 12 5 JICA 1 HIV A A HI15 10 27 12 5 JICA 1 HIV A H15 11 10 JICA HIV AIDS HIV B H15 10 27 12 5 JICA 1 HIV A 2 RH 1 HS
79. HIV HIV SHIV SHIV SHIV CD4 2 SHIV CD4 Cell Free SHIV Cell associated virus Cell associated virus
80. Xiaojie Li Yanling Ma Chaojung Yang Qiangiu Wang ME Ef 44 BB JI Xueshan Xia Kunlong Ben Min Thwe Tin Aung Kay Thi Aye Khin Yi Oo Hlat Htut Lwin AIDS STD 6 HIV 1 HIV 2 HIV HIV IDU 1997 B 2000 CRFO7 BC CRF08 BC CRFOL AE
81. CRFO01 AE AZT MAIL K70R PCR DS Wat 15 3TC X MI84V I COWIE CIE 10 L4 A3 Ww h ELA EAE BUR TEE IA Re PUPS eT YTS NID oes AGA 6 CRFOLAE E HIV 1 HIV 90 B HIV generic medicine
82. Sequential linking HIV 1 AL PAA THRE RST PE 8
83. CA WADE URER SHIV ORE 51 2003 10 27 29 H WAZ KER T 51 2003 10 27 29 k Lay Myint ig HIV 1 51 2003 10 27 29 H fu gag pol CTL 51 2003 10 H 17 18 19 20 21 22 23 24 25 26 27 28 RAT J amp
84. R5 CD4 RNA RNA HIV 2 HV Kurloff cell NK L BCG NK 2 NK human r IL2 1000U NK r IL2 GM1 NK
85. HIV 1 COO SA Os jx te S 2 HIV 1 B HIV 1 B B B B B HIV 1 ABE PCR B B106 22 B106 22 PHA PBMC Te JM_ OSE CHE Wier RO rey
86. H16 2 2 4 WHO HIV 1 WHO UNAIDS se 16 HI15 8 1 3 JST Workshop H15 9 9 10 JST Symposium His H15 10 27 12 5 JICA 1 HIV H15 12 9 14 8 H16 3 7 11 16 H15 10 27 12 5 JICA 1 HIV HI5 10 27 12 5 JICA 1 HIV H15 11 10 11 15 JICA NIH H16 3 7 11 16 H14 9 H16 2 JICA JICA PR dS H15 10 27 12 5 JICA 1 HIV
87. B106 22 CXCR4 CCR5 coreceptor X4 R5 B106 coreceptor usage V3 6 6 8 NNT B106 22 B E phe Dae ee og dc ux Wee PEM 38v C RU HS TUS 7 7 BRI xU B 3 HIV 1 C CXCR4 V3 HIV 1 C CCRS5 coreceptor CXCR4 C coreceptor
88. 1 HIV BOTS ARRO assay IL 16 Tawee Chotpitayasunondh Queen Sirikit National Institute of Child Health Paijt Warachit Ministry of Public Health 4 HIV HIV 60 HIV polyclonal Wir imp HIV monoclone oligoclone polyclonal HIV monoclonal HIV virus polyclonal M tropic virus polyclonal
89. SHIV RT RNA RNA RT RT defectiveness Te Walid Heneine CDC 7 HIV DB HIV HIV HIV DB URL https aids nih go jp DB 1989 HIV
90. HIV DNA SeV BCG SIV HIV 1 HIV HIV 1
91. RA HIV 1 17 2003 11 27 29 HIV 1 B 17 2003 11 27 29 AME Ma Yanling Yang Chaojun ET HOI Yang Rongge Ben Kunlong ICE B As ome ASS 2003 11 27 29 EE HIVRNA CBO 17 2003 11 27 29 B HIV 1 17 2003 11 27 29 RE
92. Dis Gag Do SEIEN 2 rDIsSIVGag rDIsSIVGag SIVp27 p27 ELISPOT CD4 T Gag Th1 Th2 Gag IFN y CD8 1 3 rDIs rMVA rDIsSIVGag rMVASIVGag rMVA p27 IgA
93. C B E A 1 en VIII 1 Or Ah 2 2 HIV 2 2 WHO Reference Panel WHO collaborating center National Reference Laboratory NRL Anti HIV Quality Assessment Program NRL 2 10 Genedia HIV 1 2 MIXT PA PA Genscreen HIV1 2 ELISA DAINASCREEN HIV 1 2 ICA LAV BLOT 1 WesternBlot kit 1 HIV 1 8 2 2 HIV 1 5 5 NRL ER I 1 2 3 4 5 6 7 8
94. MAGIC 5A subtyping gag Heteroduplex Mobility Analysis subtype subtype A 7 18 AG Recombinant 6 18 subtype G 2 18 3 18 MAGIC 5A Long PCR HIV Trapping System HIV 1 genome Vpr vif HIV 1 Primer Half and Half Strategy Ghana subtype A6 AG Recombinants 7 subtype G 2 N Nii Trebi IE WM Av 2 HIV 1 MAGIC 5 SEAP HIV MAGIC 5 SEAP HIV 1 SEAP HIV HIV
95. 11 HIV 1 CRFO1 AE GPOvir d4T 3TC nevirapine HIV 1 CRF01AE GPOvir iit RNA pol 44 M184I V Y181C B K103N PCR MS PCR GPOvir Veo COPIES FORO YHA Ae LEA ai
96. A HIV 1 vitro HIV 1 HIV 1 10 30 HIV 1 in vitro 1
97. HIV DS HIV 16 000 HIV HAART HAART DF
98. HIV 1 1985 5 HIV 1 HIV HIV 1 KE OM10 1 10 HIV 1p24 RT PCR HIV 1 10 3 10 6 HIV 1 p 24 103 RT PCR 3 HIV 1 HIV 1 RT PCR 6 RT
99. SHIV C2 1 KS661c 2000TCID viremia rDIs SIVgag 108 PFU 2 SIVgag IFN y ELISPOT rDIs SIVgag 4 2 10 PBMC 200 spot forming cell SFC 2 4 4 200SFC 3 500 700SFC CD4 REZ WREE 4 HIV HIV HIV 1 vit 10 vif vif
100. T CTL HLA D HIV 451 103 ADORE Sve HIV ESN 100 HLA HIV ESN HLA HLA IA B B 57 HLA B HLA HIV Br
101. 2003 6 27 29 HIV HIV 1 15 24 HIV 20034E 7 H 11 AL YS Lay Myint HIV 1 6 2003 8 1 New Host Factor Involved in the Early Phase of HIV 1 s Life Cycle HIV 2003 8 1 H AS CA WADE KES a SHIV 136 2003 10 3 5 H RET Ee REREAD T 136 2003 10 3 5 SEET
102. HIV 14 dr 2003 500 5 HIV 1 2 HBs TP HCV HTLV 1 HIV 1 2 1 2 HBsAg 4 8 HTLV 1 0 096 HCV 6 6 TP 1 0 HIV 1 4 RT PCR 1 gag env CRF02_AG 15 2003
103. A5G CD4 T SIVmac239 SIVmac239 Env CD4 A5G A5G T SIVmac239 CD4 CCR5 CD4 A5G 5 A5G 1 4 SIV V1 V2 1 A5G A5G SIVmac239
104. HIV 1 in vivo 51 2003 10 27 29 H HIV 1 B 51 2003 10 27 29 H ESSE HIV 1 CRF08 BC 51 2003 10 27 29 51 2003 10 27 29 H Als Arp2 3 51 2003 10 27 29 HIV 1lgp41 51 2003 10 27 29
105. A Kmieciak D Naito T Kaneko Y Honda M Komuro K Kozbor D Effect of partial and complete variable loop deletions of the Human Immunodeficiency virus type 1 envelope glycoprotein and the breadth of gp160 specific immune responses Virology 318 493 506 2004 Nakasone T Hara T Yoshino N Honda M Update on HIV AIDS in Japan 2003 Lu Y Essex M eds AIDS in ASIA Kluwer p73 p81 2004 Matsuo K Puthavathana P Promkhatkaew D 46 4T 48 49 50 51 52 53 Balachandra K Ruxrungtham K Hamano T Sutthent R Sittisombut N Butraporn R Sriwanthana B Boonlong J Izumi Y Yamazaki S Yamamoto N Warachit P Honda M Japan s Collaboration with Thailand in the Development of HIV AIDS Vaccine Lu Y Essex M eds AIDS in ASIA Kluwer p561 p569 2004 Hamano T Sawanpanyalert P Yanai H Piyaworawong S Hara T Sapsutthipas S Phromjai J Yamazaki S Yamamoto N Warachit P Honda M Matsuo K Determination of HIV 1 CRFOILAE gag pl7 and env V3 consensus sequences for HIV AIDS vaccine design AIDS Res Hum Retroviruses 20 337 340 2004 Takizawa M Chiba J Haga S Asano T Yamamoto N Honda M The normalization of guinea pig leukocyte fractions and lymphocyte subsets in blood and lymphoid tissues using a flow cytometric procedure Experimental Animals 53 321 329 2004 someya K Xin K Q Matsuo K Okuda K Yamamoto N Honda M A consecutive prime boost vaccination of mice with simian immunodeficiency virus
106. A5G A5G A5G 2 2 1 SIVmac239 IFN y ELISPOT assay CD4 T CD8 T 2 T T 5 A5G ARE FLAS T 0 97 p lt 0 01 A5G
107. BCG Dis HIV 1 CRFO1 AE V3 12mer c BCG Dis prime boost Dls 2 boost o V3 ATF BCG DIs boost Kruavon Balachandra NIH Thai 5 Dis modified vaccinia virus Ankara MVA HIV SIV gag pol Dis rDIsSIVgag poD amp MVA MVA239SIVgag poD MVASIV239gag pol BHK 21 CV 1 rDIsSIVgag pol
108. L Soriano V Sugiura W Phanuphak P Vandamme AM Weber J Pillay D Tanuri A Harrigan PR Camacho R Schapiro JM Katzenstein D HIV 1 subtype related differences in genotypic evolution Analysis of subtypes B and C reverse transcripase and protease sequences 11th Conference on Retrovirus and Opportunistic Infections Feb 8 11 2004 Sanfrancisco USA Takebe Y Yang R Kusagawa S Zhang C Xia X Ben K Identification of new class of HIV 1 recombinants comprised of two circulating recombinant forms CRFO07 BC and CRF08 BC in China 10th Conference on Retroviruses and Opportunistic Infections Feb 10 14 2004 Boston USA Someya K Matsuo M Sata T Yamamoto N Honda M Abortive DIs Gag recombinant in mammalian cells results in efficient virus production of vaccinia immune induction as a safe immunodeficiency virus 15th Joint Scientific Meeting of the 8 10 2004 vaccine candidate AIDS Panels US Japan CMSP Mar 19 20 2 3 4 5 6 Nashville USA Honda M Nakasone T Ami Y Izumi Y Matsuo K Kawahara M Someya K Takizawa M Hara T Horibata 5 Kanekiyo M Yamamoto N A prime boost vaccine with recombinant Mycobacterium bovis bacillus Calmette Guerin and a non replicating vaccinia virus recombinant elicitation of long lasting and positive immunity and safety study 15th Joint Scientific Meeting of the AIDS Panels US Japan CMSP Mar 8 10 2004 Nashville USA Takebe Y Yokota Y Kusaga
109. SIV gag pol DNA and recombinant vaccinia virus strain DIs elicits effective anti SIV immunity J Virol 78 9842 9853 2004 Takeda S Shiosaki K Kaneda Y Nakasatomi T Yoshizaki H Someya K Konno Y Eda Y Kino Y Yamamoto N Honda M Hemagglutinating virus of Japan HVJ protein is efficient for induction of CD4 T cell response by a hepatitis B core particle based HIV vaccine Clin Immunol 112 92 105 2004 Dewan Z Watanabe M Terashima K Aoki M Sata T Honda M Ito M Yamaoka S Watanabe T Horie R Yamamoto N Prompt tumor formation and maintenance of constitutive NF kB activity of multiple myeloma cells in NOD SCID y mice Cancer Sci 95 564 568 2004 Yamakami K Honda M Takei M Nakasone T Ami Y Kitamura N Nishinarita S Sawada S Horie T Early SHIV C2 1 infected macaques and relevance to advance of disease J Virol 78 10906 10910 2004 Myint L Matsuda M Matsuda Z Yokomaku Y Chiba T Okano A Yamada K Sugiura W Gag non cleavage site bone marrow hematopoietic defect in mutations contribute to full recovery of viral fitness in protease inhibitor resistant human immunodeficiency type 1 Antimicrob Agents Chemother 48 444 452 2004 Yokomaku Y Miura El Tomiyama H Kawana Tachikawa A Takiguchi M Kojima A Nagai Y Iwamoto A Matsuda Z Ariyoshi K Impaired processing virus 54 55 56 57 58 59 60 61 62 and presentation of
110. WOOMERA DAT NTR T RA HIV 1gp41 ORE GXXXG G GpA gp41 CD4 CD4 HIV 1 DiGi Se 2 FETA ey ie HIV 1 AIDS HIV 1 AIDS 2
111. a BD 6 HIV 222 IL4 C589T CCR2 64I CCR5 P1 RANTES G403A RANTES C28G RANTES Intl 1 RANTES 3 UTR PCR RFLP CD4 IL 4 589T CD4 RANTES 28G m
112. ISPOT rBCG 0 1mg rDIls boost 105 PBMC 2007600 spot forming cell SFC 0 01 0 03 mg 100 200 SFPC rBCG 0 1mg rDIs 10 PPU prime boost 2 SIV gag BCG rBCG SIVGag rBCG SIVGag 0 1 mg 1 80 mg 2 125 IFNy IL 10 IL 12 TGF B Rea time RT PCR 1E amp PBMC PPD Gag IFNy mRNA D PBMC fMi a CD4 CD8 Real time RT PCR CD4 PPD Gag IFNy mRNA
113. RF01 AE Gag amp HIV 1 Clade B Gag FDA Seed Lot Approval 2 TU 1 CRFO1 AE 4 Subtype E HIVgag rBCG HIVgagB rDIs HIVgagE prime boost 3 rBCG HIVgagE 0 01 0 03 0 1mg priming amp L T Vy EER C 0 RE Ic rDIs HIVgagE 10 PFU boosting 2 HIVgag IFN y EL
114. SIV Gag Dis rBCG Gag prime rDIsGag boost Gag BCG a SIV gag fit Dis boost DIsGag cw BCG a SIV gag Ds rDIs LacZ chick embryo fibroblast CEF X gal ER le GBW
115. Utsuyama M Tatsumi M Uematsu H Hirokawa K Regulation of oseteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells Biophsic Res Commun 314 1021 1027 2004 Kuroyama H Ikeda T Kasai M Yamasaki S Tatsumi M Utsuyama M Saito T Hirokawa K Identification of a novel isoform of ZAP 70 truncated ZAP kinase Biochem Biophis Res Commun 315 935 941 2004 Matano T Kobayashi M H Takeda A Nakamura H Kano M Sugimoto C Mori K jida A Hirata T Hasegawa M Yuasa T Miyazawa M Takahashi Y Yasunami M Kimura A O Connor DH Watkins DI Nagai Y Cytotoxic T lymphocyte based control of simian immunodeficiency virus replication in a J Exp Med 199 Biochem Igarashi preclinical AIDS vaccine trial 1709 1718 2004 Lun W H Takeda A Nakamura H Kano M Mori K sata T Nagai Y Matano T Loss of virus specific CD4 T cells with increases in viral loads in the chronic 63 64 phase after vaccine based partial control of primary simian immunodeficiency virus replication in macaques J Gen Virol 85 1955 1963 2004 Ansari AA Mayne AE Onlamoon N Pattanapanyasat K Mori K Villinger F Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS Immunol Res 29 1 18 2004 Barnor JS Kurosaki N Yamaguchi K Sakamoto A Ishikawa K Inagaki Y Yamamoto N Osei Kwasi M Ofori Adjei D Takaku H Intracellular expression of anti sense RNA ta
116. _AE 228 B 9 CRF02_AG 1 Pil gag B env CRFO1AE 1 B env B B 13 2003 12 500 5 HIV 1 2 fit HBs TP HCV HTLV 1 HBsAg 12 6 TP 12 0 HCV 10 2 HIV 33 6 HTLV 1 0 0 46 4 1 HIV
117. ad Sci USA 100 2777 2782 2003 Yoshida A Tanaka R Murakami T Takahashi Y Koyanagi Y Nakamura M Ito M Yamamoto N Tanaka Y Induction of protective immune responses against R5 human immunodeficiency virus type 1 HIV 1 infection in hu PBL SCID mice by intrasplenic immunization with HIV 1 pulsed dendritic cells possible involvement of a novel factor of human CD4 T cell origin J Virol 11 8719 8728 2003 Mori N Krensky AM Geleziunas R Wada A Hirayama T Sasakawa C Yamamoto N Helicobacter pylori induces RANTES through activation of NF kappa B Infect Immun 71 3748 3756 2003 Mori N Morishita M Tsukazaki T Yamamoto N Repression of Smad dependent transforming growth factor beta signaling by Epstein Barr virus latent membrane protein 1 through nuclear factor kappaB Int J Cancer 105 661 668 2003 Shuda M Kondoh N Imazeki N Tanaka K Okada T 36 37 38 39 40 41 42 43 44 45 Mori K Hada A Arai M Wakatsuki T Matsubara O Yamamoto N Yamamoto M Activation of the ATF6 XBP1 carcinoma a possible involvement of the ER stress J Hepatol 38 and grp78 genes in human hepatocellular pathway in hepatocarcinogenesis 605 614 2003 Nitta T Chiba A Yamashita A Rowe M Israel A Reth M Yamamoto N Yamaoka S NF kappaB is required for cell death induction by latent membrane protein 1 of Epstein Barr virus Cell Signal 15 423 433 2003 s
118. ai K Takahashi E Shinohara K Suzuki H Ibuki K Hayami M Comparative analysis of acute pathogenic and less pathogenic SHIV molecular clones Japan U S Medical Program 15th Joint Meeting of AIDS Panel Mar 4 7 2003 Ginowan Japan Miyauchi K Komano J Yokomaku Y Matsuda Z The role of the membrane spanning domain of HIV 1 TM in Cooperative Science membrane fusion Retroviruses Cold Spring Harbor Laboratory May 20 25 2003 Cold Spring Harbor NY 5 6 7 8 9 10 11 USA Myint L Matsuda M Chiba T Yan H Kakizawa J Okano A Hamatake M Nishizawa M Sugiura W Analysis of virion morphology and assembly pricess in protease inhibitor resistant HIV 1 12th International HIV Drug Resistance Workshop Jun 10 14 2003 Cabo SanLucas Mexico Kantor R Shafer RW Carvalho AP Wynhoven B soares MA Cane P Clarke J Snoeck J Pillay C sirivichayakul S Ariyoshi K Holguin A Grossman Z Rodrigues R Bouzas MB Cahn P Brigido LF Soriano V Sugiura W Phanuphak P Morris L Vandamme A M Weber J Pillay D Tan A Katzenstein D Nucleic acid HIV 1 transcriptase and protease sequences at drug resistance positions 12th International HIV Drug Resistance Workshop Jun 10 14 2003 Cabo SanLucas Mexico Snoeck J Kantor R Shafer RW Derdelinckx I Carvalho AP Wynhoven B Soares MA Cane P Clarke J Pillay C Sirvichayakul S Ariyoshi K Holguin A Grossman Z Rodrigues R Bouzas MB Cahn P Brigido LF So
119. coreceptor 96USNG31 HIV 1 C coreceptor env V3 coreceptor 96USNG31 4 V3 CCR5 IndieC1 3 coreceptor 21YOH 23TH 32QK coreceptor 23T H 32Q K CCR5 21Y gt H 23TH 2 CXCR4 CCR5 HIV 1 C coreceptor env V3 CXCR4 21
120. cytotoxic T lymphocyte CTL epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type J Virol 78 1324 1332 2004 saeng Aroon S Wichukchinda N Myint L Pathipvanich P Ariyoshi K Rojanawiwat A Matsuda M sawanpanyalert P Sugiura W Auwanit W Study of HIV 1 role of mutagenically separated infection antiretroviral drug resistant genotypes in northern Thailand polymerase chain reaction as a tool for monitoring zidovudine resistant HIV 1 in resource limited settings J Acquir Immune Defic Syndr 36 1051 1056 2004 Takamura S Niikura M Li T C Takeda N Kusagawa S Takebe Y T Yasutoml Y DNA vaccine encapsulated virus like particles derived from Miyamura an orally transmissible virus stimulates mucosal and systemic immune responses by oral administration Gene Ther 11 628 635 2004 Takebe Y Kusagawa S Motomura K Moleucular epidemiology of HIV Tracking AIDS Pandemic Pediatr Int 46 236 244 2004 Arita I Nakane M Kojima K Yoshihara N El Gohary A Role of a sentinel surveillance system in the context of global surveillance of infectious diseases Lancet Infect Dis 5 172 177 2004 Harada T Tatsumi M Takahashi H Sata T Kurata T Kojima A Specific reactions between purifyied HIV 1 particles and CD4 cell membrane fragments in a cell free system of virus fusion or entry Microbes Infection 6 421 428 2004 suzuki J Ikeda T Kuroyama H Seki S Kasai M
121. drug resistance assay for three drug combination therapies that takes into consideration in vivo drug concentrations J Virol Methods 111 43 53 2003 sugimoto C Tadakuma K Otani I Moritoyo T Akari H Ono F Yoshikawa Y Sata T Izumo S Mori K Nef gene is required for robust productive infection of simian immunodeficiency virus in T cell rich paracortex in lymph nodes J Virol 77 4169 4180 2003 Xing HQ Moritoyo T Mori K Tadakuma K Sugimoto C Ono F immunodeficiency virus encephalitis in the white matter of the simian virus infected monkey J Neurovirol 9 508 518 2003 Villinger F Mayne AF Bostik P Mori K Jensen PE Ahmed R Ansari A Evidence for antibody mediated enhancement of SIVgag antigen processing and cross J Virol Hayakawa H Izumo S Simian and degeneration cerebral cortex occur independently in immunodeficiency presentation in SIV infected rhesus macaques TT 10 24 2003 Kennedy G Komano J Sugden B Epstein Barr virus provides a survival factor to Burkitt s lymphomas Proc Natl Acad Sci U S A 100 24 14269 14274 2003 Fukushi M Higuchi M Oie M Tetsuka T Kasolo F Ichiyama K Yamamoto N Katano H Sata T Fujii M Latency associated nuclear antigen of Kaposi s sarcoma associated herpesvirus interacts with human myeloid cell nuclear differentiation antigen induced by interferon alpha Virus Genes 27 237 247 2003 21 28 29 30 31 32 33 34 35 Dewan MZ Tera
122. lence of diverse forms of intersubtype recombinants in Central Myanmar geographical hot spot of extensive recombination AIDS 17 2077 2087 2003 Kusagawa S Imamura Y Yasuoka A Hoshino H Oka S Takebe Y of HIV 2 transmission in East Asia AIDS Res Hum Retroviruses 19 11 1045 1049 2003 Identification subtype B 18 19 20 21 22 23 24 25 26 suzuki S Sugauchi F Orito E Kato H Usuda S Siransy L Arita I Sakamoto Y Yoshihara N El Gohary A Ueda R Mizokami M Distribution of hepatitis B virus HBV genotypes among HBV carriers in the Cote d Ivoire complete genome sequence and phylogenetic relatedness of HBV genotype E J Med Virol 69 459 465 2003 sugauchi F Orito E Kato H Suzuki S Kawakita S sakamoto Y Fukushima K Akiba T Yoshihara N Ueda R Mizokami M Genotype serotype and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers ofthe virus J Med Virol 69 33 40 2003 sakamoto T Ushijima H Okitsu S Suzuki E Sakai K Morikawa S M ller WEG Establishment of an HIV cell cell fusion assay by using two genetically modified HeLa cell lines and reporter gene J Virol Methods 114 159 166 2003 Hachiya A Matsuoka Aizawa S Tsuchiya K Gatanaga H Kimura S Tatsumi M Oka S All in One Assay a direct phenotypic anti human immunodeficiency virus type 1
123. nscripts complementary to the human immunodeficiency virus type 1l vif gene inhibits viral replication in infected T lymphoblastoid cells BBRC 320 544 550 2004 2 1 2 3 4 5 6 0 8 9 10 11 12 41 731 737 2003 AL HIV 35 6 113 118 2003 HIV 1 BW 31 4 212 282 2003 FHT HIV 5 109 112 2003 3 194 196 2003 ELA HIV HIV 31 283 291 2003 HEX 2003 in press Es Uk ua HIV 1 CRF lt gt 2003 91 6 2003 8 10
124. riano V Sugiura W Phanuphak P Morris L Weber J Pillay D Tanuri A Harrigan PR Camacho R Schapiro JM AM Evaluation of five interpretation algorithms for the differences between non B and reverse Katzenstein D Vandamme prediction of drug susceptibility in non B subtype 12th International HIV Drug Resistance Workshop Jun 10 14 2003 Cabo SanLucas Mexico Totani R Hayashi K Hasuo S Kita T Takahashi S Yoshino N Wada Y Togawa M Tsukahara Y HIV mother to child vertical infection in Japan A national 2 th Annual Meeting of the Society for Reproductive Immunology Jun 18 22 2003 New Haven USA Hayashi K Kita T Hasuo Y Totani R Yoshino N Wada Y Hayakawa S Tukahara Y Takano M H Minoura S N The clinical assessment of maternal HIV testing in early pregnancy 2 th Meeting of the Society for Reproductive Immunology Jun 18 22 2003 New Haven USA Ibuki K Enose Y Miyake A Suzuki H Takahashi M Horiuchi R Saito N Nakasone T Ami Y Izumi Y Honda M Takahashi H Miura T Hayami M Analysis of viral expansion and immune reaction at early phase of SHIV macaques 21th Annual Symposium on Nonhuman Primate Models for AIDS Oct 22 25 2003 Seattle USA Suzuki H Suzuki M Ibuki K Masuda K Minato N co operative study report Taniguchi Inaba to prevent mother to child transmission in Japan Annual acute pathogenic intrarectal infection in 12 13 14 15 16 17 18
125. shi H Nakamura H Kano M jida A Hirata T Hasegawa M Nagai Y Matano T Protective antiretroviral drug treatment failure efficacy of an AIDS vaccine a single DNA prime followed by a single booster with a recombinant replication defective Sendai virus vector in a macaque AIDS model J Virology 77 9710 9715 2003 Matsuoka Aizawa S Sato H Hachiya A Tsuchiya K Takebe Y Gatanaga H Kimura S Oka S Isolation and Nelfinavir molecular characterization of a NFV resistant human immunodeficiency virus type 1 that exhibits NFV dependent replication J Virol 77 1 318 327 2003 Yang R Kusagawa S Zhang C Xia X Ben K Takebe Y Identification and characterization of new class of enhancement of comprised of two circulating recombinant forms CRFOY BC and CRF08 BC in China J Virol 77 1 685 695 2003 Motomura K Kusagawa S Lwin HH Thwe M Kato K Ohishi K Yamamoto N Zaw M Nagatake T Takebe Y Different subtype distribution in the two cities in HIV 1 recombinants Myanmar evidence for independent clusters of HIV 1 transmission AIDS 17 4 14 17 2003 Kaizu M Sato H Ami Y Isumi Y Nakasone T Tomita Y Someya K Takebe Y Kitamura K Tochikubo O Honda M Infection of macaques with an R5 tropic SHIV bearing a chimeric envelope carrying subtype E V3 loop among subtype B framework Arch Virol 148 5 973 988 2003 Takebe Y Motomura K Tatsumi M Lwin HH Zaw M Kusagawa K High preva
126. shima K Taruishi M Hasegawa H Ito M Tanaka Y Mori N Sata T Koyanagi Y Maeda M Kubuki Y Okayama A Fuji M Yamamoto N Rapid tumor formation of human T cell leukemia virus type 1 infected cell lines in novel NOD SCID gammac null mice suppression by an inhibitor against NF kappaB J Virol 77 5286 5294 2003 Mori N Sato H Hayashibara T Senba M Geleziunas R Wada A Hirayama T Yamamoto N Helicobacter pylori induces matrix metalloproteinase 9 through activation of nuclear factor kappaB Gastroenterology 124 983 992 2003 Handema R Terunuma H Kasolo F Kasai H Sichone M Yamashita A Deng X Mulundu G Ichiyama K Munkanta M Yokota T Wakasugi N Tezuka F Yamamoto N Ito M drug resistance associated mutations in antiretroviral Prevalence of drug naive Zambians infected with subtype C HIV 1 AIDS Res Hum Retroviruses 19 151 160 2003 Ichiyama K Yokoyama Kumakura S Tanaka Y Tanaka R Hirose K Bannai K Edamatsu T Yanaka M Niitani Y Miyano Kurosaki N Takaku H Koyanagi Y Yamamoto N A duodenally absorbable CXC chemokine receptor 4 antagonist KRH 1636 exhibits a potent and selective anti HIV 1 activity Proc Natl Acad Sci USA 100 4185 4190 2003 Miura Y Misawa N Kawano Y Okada H Inagaki Y Yamamoto N Ito M Yagita H Okumura K Mizusawa H Koyanagi Y Tumor necrosis factor related apoptosis inducing ligand induces neuronal death in a murine model of HIV central nervous system infection Proc Natl Ac
127. tiviral Ther 8 S111 2003 sugiura W Shimada K Matsuda M Chiba T Myint L Okano A Yamada K Novel genotyping assay for human immunodeficiency virus type 1 drug resisitance using enzyme linked mini sequuence assay J Clin Microbiol Al 4971 4979 2003 Ariyoshi K Berry N Cham F Jaffar S Schim van der Loeff M Jobe O N Gom PT Larsen O Andersson S Aaby P Whittle H Quantification T lymphotropic virus type I HTLV I provirus load in of Human a rural West African population no enhancement of human immunodeficiency virus type 2 pathogenesis but HTLV I provirus load relates to mortality J Infect Dis 188 1648 1651 2003 Schim van der Loeff MF Hansmann A Awasana AA Ota MO O Donovan D Sarge Njie R Ariyoshi K Milligan P Whittle H Survival of HIV 1 and HIV 2 9 10 11 12 13 14 15 16 17 perinatally infected children in The Gambia AIDS 17 2389 2394 2003 Ariyoshi K Matsuda M Miura H Tateishi S Yamada K sugiura W Patterns of point mutations associated with in CRF01 AE subtype E infection differ from subtype B infection J Acquir Immune Defic Syndr 33 336 342 2003 Alabi AS Jaffar S Ariyoshi K Blanchard T Schim van der Loeff M Awasana AA Corrah T Sabally S sarge Njie R Cham Jallow F Jaye A Berry N Whittle H Plasma viral load CD4 cell percentage HLA and survival of HIV 1 HIV 2 and dually infected Gambian patients AIDS 17 1513 1520 2003 Takeda A Igara
128. uzuki Y Misawa N Sato C Ebina H Masuda T Yamamoto N Koyanagi Y Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real time PCR integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells Virus Genes 27 177 188 2003 saito N Courtois G Chiba A Yamamoto N Nitta T Hironaka N Rowe M Yamaoka S Two C terminus activation regions of Epstein Barr virus latent membrane protein 1 activate NF kB through distinct signaling pathways in fibroblast cell lines J Biol Chem 278 46565 46575 2003 Nowell MA Richards PJ Horiuchi S Yamamoto N Rose John S Topley N Williams AS Jones SA Soluble IL 6 receptor governs IL 6 activity in experimental arthritis blockade of arthritis severity by soluble glycoprotein 130 J Immunol 171 3202 3209 2003 Tamamura H Hori A Kanzaki N Hiramatsu K Mizumoto M Nakashima H Yamamoto N Otaka A Fuji N T140 analogs as CXCR4 antagonists identified as anti metastatic agents in the treatment of breast cancer FEBS Lett 550 79 83 2003 saitoh T Nakayama M Nakano H Yagita H Yamamoto N Yamaoka S TWEAK induces NF kappaB2 p100 processing and long lasting NF kappaB activation J Biol Chem 278 36005 36012 2003 Baba S Takahashi K Koyanagi Y Yamamoto N Takaku H Gorelick RJ Kawai G Role of the zinc fingers of HIV 1 nucleocapsid protein in maturation of genomic RNA J Biochem Tokyo 134 637 639 2003 Gzyl J Bolesta E Wierzbicki
129. wa S Imamura Y Uehara R Ma Y Yang C Li X Li X Yamamuro M Thwe M Aung T Oo KY Lwin HH Precise mapping of HIV 1 recombinant forms circulating in Myanmar recombination breakpoints of unique in VIVO sequence preference for recombination and the biological implications 16th Joint Scientific Meeting of the AIDS Panels U S Japan Cooperative Medical Science Program Mar 8 11 2004 Nashville USA 135 2003 3 30 4 1 HIV 2 77 2003 4 17 18 H BRR ANTT Kunlong Ben HIV 77 2003 4 17 18 RH
Download Pdf Manuals
Related Search